期刊文献+

多国植物药专利申请状况比较研究及我国企业应对 被引量:4

Comparative Study of Patent Application Situation for Herbal Drugs in Different Countries and its Revelation of Enterprises in China
下载PDF
导出
摘要 现代专利保护对以传统药物为基础的植物药产业的可持续发展和国际化有着深刻的影响。我国中药大部分可归为植物药范畴,但目前中药企业应用专利保护制度的能力还较为薄弱。分析中国、日本、韩国、美国、欧盟、印度等国家和地区针对植物药专利在其母国的申请情况、在中国的申请情况以及向外申请情况。同时,结合我国重点中药企业在欧美的专利布局提出建议,以期加强企业对于中药知识产权的保护意识,重视全球布局。 Patent protection system has a profound impact on the sustainable development and internationalization of herbal drugs based on the traditional medicine.However,the ability of Chinese enterprises in applying the current system of patent protection is still weak.In this article,the patent application situation for herbal drugs is analyzed and compared,by using the data of China,Japan,Republic of Korea,the United States,European Union and India,based on their domestic patent applications,Chinese patent applications and the foreign patent applications.In the meantime,combined with patent port-folio of key Chinese medicine enterprises in Europe and US,this article also gives some suggestions for strengthening the awareness of intellectual property protection of traditional Chinese medicine and the global layout.
出处 《科技管理研究》 CSSCI 北大核心 2014年第16期156-161,共6页 Science and Technology Management Research
基金 中央高校基本科研业务费项目"中药科技与中药国际保护和推广研究"(WT1221002)
关键词 植物药 中药 专利保护 专利布局 botanical drug Chinese traditional medicine patent protection patent portfolio
  • 相关文献

参考文献12

  • 139健康网.中成药市场份额集中,前十药企占总额1/4 [EB/OL]. (2012 - 12 — 04) [2014 — 03 — 10]. http://drug.39.net/a__zhlt/121204/4092362. html.
  • 2中国经营报.中药受阻“标准化”,日韩垄断海外市场[EB/OL]. (2013 - 12 -30) [2014 -03 - 10]. http://news. cb. com. cn/html/ company」1 _16086_1. html.
  • 3虞忠,卞鹰,胡元佳,王一涛.我国中药占国际市场份额的测算及相关概念辨析[J].中国药房,2006,17(5):328-330. 被引量:10
  • 4张晓东.医药专利制度比较研究及典型案例[M].北京:知识产权出版社,2012.
  • 5杨年富.中药国际保护研究[J].前沿,2011(23):27-31. 被引量:2
  • 6米内网.中国医药上市公司竞争力排行榜.2010年中药(含饮片)类上市企业综合竞争力排名前10位[EB/OL]. [2014-01-21 ] . http://www. menet. com. cn/Subject/templets/2011 shb/.
  • 7新华网.天士力复方丹参滴丸海外临床三期认证启动[EB/OL].(2012 - 09 - 21 ) [2014 - 03 - 10]. http://news, xinhuanet. com/fortune/2012 -09/21/c_123743589. htm.
  • 8CLINICALTRIALS. ClinicalTrials. gov. studies found for: Tasly.[EB/OL]. [2014 -01 -25]. http://clinicaltrials. gov/ct2/results.term = Tasly.
  • 9腾讯健康.中药扶正化瘀片成功完成美国II期临床试验[EB/OL]. (2013 -11 -05) [2014 -03 - 10]. http://health, qq. com/a/20131105/011407/htm.
  • 10搜狐证券.兰州佛慈制药股份有限公司2013年半年度报告[EB/OL]. ( 2013 - 08 - 19 ) [ 2014 - 03 - 10 ] http://q. stock, sohu. com/cn/gg/118/386/11838681. shtml.

二级参考文献24

  • 1张清奎.谈谈中国对药品的知识产权保护[J].知识产权,2002,12(2):15-19. 被引量:7
  • 2徐晋红.关于中药保护的思考[J].国际医药卫生导报,2005,11(3):92-94. 被引量:5
  • 3段慧敏,孙利华,金丹风.中药申请专利和技术秘密的经济性评价[J].中国现代中药,2006,8(3):39-41. 被引量:1
  • 4华鹰.中药标准化和中药专利保护与中药现代化[J].中国科技论坛,2006(6):61-65. 被引量:6
  • 5U.S.Food and Drug Administration.Guidance for industry botanical drug products[EB/ OL].http://www.fda.gov/cder/guidance/4592fnl.htm.
  • 6Directive 2004/24/ec of the european parliament and of the council of 31 March 2004,amending,as regards traditional herbal medicinal products,directive 2001/ 83/ EC on the community code relating to medicinal products for human use,official journal L 136,30/4/2004:85~ 90[EB/OL].http://www.emea.eu.int.
  • 7萧照贞 邱哲杰.日本汉方药产业概况[EB/OL].http://www.nri.com.tw/d/pdf/Repout/02/008/01/02_008_01_00.pdf.,.
  • 8Robert R.Overview of the global herb marketplace[EB/OL].http://www.rirdc.gov.au/reports/EOI/04 -059.pdf.
  • 9ProFound.Natural ingredients for pharmaceuticals(eu market survey 2003)[EB/OL].http://www.proexport.com.co/ VBeContent/ library/documents/ DocNews-No2745DocumentN 02493.PDF.
  • 10中国医药统计年报编辑部.中国医药统计年报(2003)[EB/OL].http://www.bj-jq.com/newbjjqweb/chanpinfuwu/book/zgyytjnb.htm.,.

共引文献10

同被引文献24

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部